First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial
在中国RAS/BRAF野生型转移性结直肠癌患者中，一线治疗方案为抗EGFR单克隆抗体西妥昔单抗β联合FOLFIRI方案与单用FOLFIRI方案的比较：一项随机、3期临床试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02229-4
Shi, Yuankai; Ba, Yi; Wang, Junye; Xiong, Jianping; Gu, Kangsheng; Chen, Yigui; Zheng, Zhendong; Wang, Zishu; Guo, Weijian; Cheng, Ying; Yin, Xianli; Liu, Yunpeng; Bai, Yuxian; Li, Enxiao; Li, Qi; Zhu, Liangjun; Li, Wei; Jiang, Da; He, Jingdong; Chen, Jiansi; Sun, Jianguo; Hou, Sheng
单克隆抗体
肿瘤
肠癌
肿瘤免疫
EGF
BRAF
EGFR
RAS
